The stock of Masimo Corporation (NASDAQ:MASI) hit a new 52-week high and has $66.36 target or 6.00% above today’s $62.60 share price. The 6 months bullish chart indicates low risk for the $3.13 billion company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $66.36 price target is reached, the company will be worth $187.80M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 0.82% or $0.51 during the last trading session, hitting $62.6. About 126,780 shares traded hands. Masimo Corporation (NASDAQ:MASI) has risen 43.30% since April 22, 2016 and is uptrending. It has outperformed by 37.89% the S&P500.
Analysts await Masimo Corporation (NASDAQ:MASI) to report earnings on February, 28. They expect $0.51 EPS, up 240.00% or $0.36 from last year’s $0.15 per share. MASI’s profit will be $25.50M for 30.69 P/E if the $0.51 EPS becomes a reality. After $0.47 actual EPS reported by Masimo Corporation for the previous quarter, Wall Street now forecasts 8.51% EPS growth.
Masimo Corporation (NASDAQ:MASI) Ratings Coverage
Out of 3 analysts covering Masimo (NASDAQ:MASI), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Masimo has been the topic of 3 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Wednesday, January 6 by Raymond James. The rating was maintained by TH Capital on Wednesday, August 5 with “Buy”.
According to Zacks Investment Research, “Masimo develops innovative monitoring technologies that significantly improve patient care — helping solve unsolvable problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry’s ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.”
Insitutional Activity: The institutional sentiment increased to 1.33 in Q2 2016. Its up 0.01, from 1.32 in 2016Q1. The ratio is positive, as 14 funds sold all Masimo Corporation shares owned while 85 reduced positions. 52 funds bought stakes while 79 increased positions. They now own 38.69 million shares or 0.37% less from 38.84 million shares in 2016Q1.
Moreover, Price T Rowe Associate Md has 0.01% invested in Masimo Corporation (NASDAQ:MASI) for 466,280 shares. Blackrock Institutional Trust Na reported 1.43 million shares or 0.01% of all its holdings. Usa Fincl Portformulas holds 0.25% or 17,021 shares in its portfolio. Thrivent For Lutherans accumulated 0.01% or 21,400 shares. Impact Advsr Ltd Liability has 0.58% invested in the company for 23,427 shares. Old Mutual Global (Uk) accumulated 278,941 shares or 0.27% of the stock. Cubist Systematic Strategies Llc holds 0.03% or 11,156 shares in its portfolio. Nomura last reported 0% of its portfolio in the stock. Goldman Sachs Gp Inc reported 145,842 shares or 0% of all its holdings. Bridgeway Cap Mgmt Inc holds 10,700 shares or 0.01% of its portfolio. Oxford Asset Management last reported 0.3% of its portfolio in the stock. Pacad Invest reported 5,153 shares or 0.04% of all its holdings. Janney Capital Mgmt Llc holds 0.01% of its portfolio in Masimo Corporation (NASDAQ:MASI) for 3,918 shares. Paradigm Asset Mgmt Co Limited has 0% invested in the company for 2,500 shares. Segall Bryant & Hamill Ltd Co has invested 0.14% of its portfolio in Masimo Corporation (NASDAQ:MASI).
Insider Transactions: Since May 31, 2016, the stock had 0 insider purchases, and 27 insider sales for $33.69 million net activity. Lee Yongsam also sold $1.82 million worth of Masimo Corporation (NASDAQ:MASI) on Monday, October 10. FITCH SANFORD sold $118,825 worth of stock. 22,000 shares with value of $1.25 million were sold by Coleman Jon on Thursday, August 4. KIANI JOE E sold $84,032 worth of stock. 5,000 shares were sold by Van Ramshorst David J, worth $262,500. On Monday, October 31 Sampath Anand sold $3.58 million worth of the stock or 65,000 shares. Another trade for 40,000 shares valued at $1.98M was sold by de Raad Mark.
MASI Company Profile
Masimo Corporation, incorporated on May 7, 1996, is a medical technology firm that develops, makes and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. The Company’s product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. It has also developed the Patient SafetyNet remote patient surveillance monitoring system, which allows over 200 patients to be monitored simultaneously and remotely through a personal computer (PC) viewing station or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.